Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 3, 2015, Pages

  Achkar, Jacqueline M ^a   Chan, John ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MONOCLONAL ANTIBODY; BACTERIUM ANTIBODY;

ARTICLE; B LYMPHOCYTE; BCG VACCINATION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TREATMENT OUTCOME; TUBERCULOSIS; ANIMAL; CELLULAR IMMUNITY; IMMUNOLOGY; MACROPHAGE; MOUSE; T LYMPHOCYTE;

MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS VACCINES;

EID: 84923886417     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a018432     Document Type: Article

References (155)

1. Abel L, Casanova JL. 2000. Genetic predisposition to clinical tuberculosis: Bridging the gap between simple and complex inheritance. Am J Hum Genet 67: 274-277.
2. Achkar JM, Jenny-Avital ER. 2011. Incipient and subclinical tuberculosis: Defining early disease states in the context of host immune response. J Infect Dis 204 (Suppl): S1179-S1186.
3. Achkar JM, Casadevall A. 2013. Antibody-mediated immunity against tuberculosis: Implications for vaccine development. Cell Host Microbe 13: 250-262.
4. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 55: 1527-1532.
5. Almeida LP, Trombone AP, Lorenzi JC, Rocha CD, Malardo T, Fontoura IC, Gembre AF, Silva RL, Silva CL, Castelo AP, et al. 2011. B cells can modulate the CD8 memory T cell after DNAvaccination against experimental tuberculosis. Genet Vaccines Ther 9: 5.
6. Armstrong JA, Hart PD. 1971. Response ofcultured macro-phages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 134: 713-740.
7. Armstrong JA, Hart PD. 1975. Phagosome-lysosome interac-tionsinculturedmacrophagesinfectedwithvirulenttuber-cle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. JExp Med 142:1-16.
8. Ballow M. 2011. The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127: 315-323; quiz 324-315.
9. Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Koo-ten C, van Egmond M, Challacombe S, Woof JM, Ivanyi J. 2011. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 186: 3113-3119.
10. Beyazova U, Rota S, Cevheroglu C, Karsligil T. 1995. Humoral immune response in infants after BCG vaccination. Tuber Lung Dis 76: 248-253.
11. Boggian K, Fierz W, Vernazza PL. 1996. Infrequent detection oflipoarabinomannan antibodies in human immunodeficiency virus-associated mycobacterial disease. Swiss HIV cohort study. JClin Microbiol 34: 1854-1855.
12. Bosio CM, Gardner D, Elkins KL. 2000. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: Delay in dissemination and development of lung pathology. J Immunol 164: 6417-6425.
13. Bruton OC. 1952. Agammaglobulinemia. Pediatrics 9:722-728.
14. Buccheri S, Reljic R, Caccamo N, Ivanyi J, Singh M, Salerno A, Dieli F. 2007. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol 37: 729-737.
15. Buccheri S, Reljic R, Caccamo N, Meraviglia S, Ivanyi J, Salerno A, Dieli F. 2009. Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. Tuberculosis (Edinb) 89: 91-94.
16. Carroll MV, Lack N, Sim E, Krarup A, Sim RB. 2009. Multiple routes of complement activation by Mycobacterium bovis BCG. Mol Immunol 46: 3367-3378.
17. Casadevall A. 1995. Antibody immunityand invasive fungal infections. Infect Immun 63: 4211-4218.
18. Casadevall A. 1998. Antibody-mediated protection against intracellular pathogens. Trends Microbiol 6: 102-107.
19. Casadevall A. 2003. Antibody-mediated immunity against intracellular pathogens: Two-dimensional thinking comes full circle. InfectImmun 71:4225-4228.
20. Casadevall A. 2004. The methodology for determining the efficacy of antibody-mediated immunity. J Immunol Methods 291: 1-10.
21. Casadevall A, Pirofski LA. 2003. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1: 17-24.
22. Casadevall A, Pirofski LA. 2012a. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11: 447-456.
23. Casadevall A, Pirofski LA. 2012b. A new synthesis for antibody-mediated immunity. Nat Immunol 13: 21-28.
24. Casadevall A, Dadachova E, Pirofski LA. 2004. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2: 695-703.
25. Casanova JL, Abel L. 2002. Genetic dissection of immunity to mycobacteria: The human model. Annu Rev Immunol 20: 581-620.
26. Cassone A, Casadevall A. 2012. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol 15: 427-433.
27. Chambers MA, Gavier-Widen D, Hewinson RG. 2004. Antibody bound to the surface antigen MPB83 ofMycobac-terium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 41: 93-100.
28. Chan AC, Carter PJ. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301-316.
29. Chang-hong S, Xiao-wu W, Hai Z, Ting-fen Z, Li-Mei W, Zhi-kai X. 2008. Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis. DNA Cell Biol 27: 199-207.
30. Chow SK, Smith C, MacCarthy T, Pohl MA, Bergman A, Casadevall A. 2013. Disease enhacing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe 13: 417-428.
31. Ciurana CL, Zwart B, van Mierlo G, Hack CE. 2004. Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM. Eur J Immunol 34: 2609-2619.
32. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, King EC, Lukey PT, Duncan K, Van Helden PD, et al. 2013. Distinct phases ofblood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 207: 18-29.
33. Clynes R. 2005. Immune complexes as therapy for autoim-munity. J Clin Invest 115: 25-27.
34. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698-702.
35. Collins FM. 1974. Vaccines and cell-mediated immunity. Bacteriol Rev 38: 371-402.
36. Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, Howard V, Campana D. 2009. Primary B cell immunodeficiencies: Comparisons and contrasts. Annu Rev Immunol 27: 199-227.
37. Conti S, Fanti F, Magliani W, Gerloni M, Bertolotti D, Salati A, Cassone A, Polonelli L. 1998. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 177: 807-811.
38. Cooper AM. 2009. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
39. Corominas M, Cardona V, Gonzalez L, Cayla JA, Rufi G, Mestre M, Buendia E. 2004. B-lymphocytes and co-stimulatory molecules in Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis 8: 98-105.
40. Costello AM, Kumar A, Narayan V, Akbar MS, Ahmed S, Abou-Zeid C, Rook GA, Stanford J, Moreno C. 1992. Does antibody to mycobacterial antigens, including lip-oarabinomannan, limit dissemination in childhood tuberculosis? Trans R Soc Trop Med Hyg 86: 686-692.
41. Cruz AT, Starke JR. 2007. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev 8: 107-117.
42. Cubas RA, Mudd JC, Savoye AL, Perreau M, van Greve-nynghe J, Metcalf T, Connick E, Meditz A, Freeman GJ, Abesada-Terk G Jr., et al. 2013. Inadequate T follicularcell help impairs B cell immunity during HIV infection. Nat Med 19: 494-499.
43. Czuczman MS, Gregory SA. 2010. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 51: 983-994.
44. Dayal R, Singh A, Katoch VM, Joshi B, Chauhan DS, Singh P, Kumar G, Sharma VD. 2008. Serological diagnosis of tuberculosis. Indian J Pediatr 75: 1219-1221.
45. de Valliere S, Abate G, Blazevic A, Heuertz RM, Hoft DF. 2005. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 73: 6711-6720.
46. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bon-vini E, Koenig S, Steinman RM, Ravetch JV, Dhodapkar MV 2005. Selective blockade of inhibitory Fcg receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci 102: 2910-2915.
47. Donald PR, Marais BJ, Barry CE, 3rd. 2010. Age and the epidemiology and pathogenesis of tuberculosis. Lancet 375: 1852-1854.
48. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 3181-3195.
49. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. InfectImmun 55: 749-752.
50. Encinales L, Zuniga J, Granados-Montiel J, Yunis M, Grana-dos J, Almeciga I, Clavijo O, Awad C, Collazos V, Vargas-Rojas MI, et al. 2010. Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Mol Immunol 47: 1066-1073.
51. Ernst JD. 2012. The immunological life cycle oftuberculosis. Nat Rev Immunol 12: 581-591.
52. Fairchok MP, Rouse JH, Morris SL. 1995. Age-dependent humoral responses ofchildren to mycobacterial antigens. Clin Diagn Lab Immunol 2: 443-447.
53. Fletcher HA, Tanner R, Wallis RS, Meyer J, Manjaly ZR, Harris S, Satti I, Silver RF, Hoft D, Kampmann B, et al. 2013. Inhibition ofmycobacterial growth in vitro following primary but not secondary vaccination with BCG. Clin Vaccine Immunol 20: 1683-1689.
54. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
55. Flynn JL, Klein E. 2010. Pulmonary tuberculosis in monkeys. In A color atlas ofcomparative pulmonarytuberculo-sis histopathology (ed. Leong J). Taylor & Francis, Oxford.
56. Fortin A, Abel L, Casanova JL, Gros P. 2007. Host genetics of mycobacterial diseases in mice and men: Forward genetic studies of BCG-osis and tuberculosis. Ann Rev Genomics Hum Genet 8: 163-192.
57. Giri PK, Verma I, Khuller GK. 2006. Enhanced immuno-protective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobac-terium tuberculosis challenge following intranasal administration. FEMS Immunol Med Microbiol 47: 233-241.
58. Glatman-Freedman A. 2006. The role ofantibody-mediated immunity in defense against Mycobacterium tuberculosis: Advances toward a novel vaccine strategy. Tuberculosis (Edinb) 86: 191-197.
59. Glatman-Freedman A, Casadevall A. 1998. Serum therapy for tuberculosis revisited: Reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11: 514-532.
60. Glatman-Freedman A, Mednick AJ, Lendvai N, Casadevall A. 2000. Clearance and organ distribution of Mycobacte-rium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M. Infect Immun 68: 335-341.
61. Glatman-Freedman A, Casadevall A, Dai Z, Jacobs WR Jr., Li A, Morris SL, Navoa JA, Piperdi S, Robbins JB, Schneerson R, et al. 2004. Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabi-nomannan. J Clin Microbiol 42: 3225-3231.
62. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. 2001. Temporal and spatial arrange-mentoflymphocyteswithinlunggranulomasinducedby aerosol infection with Mycobacterium tuberculosis. Infect Immun 69: 1722-1728.
63. Good RA, Zak SJ. 1956. Disturbances in g globulin synthesis as experiments of nature. Pediatr Rev 18: 109-149.
64. Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment: An underestimated adversary. Anti-microb Agents Chemother 47: 833-836.
65. Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller GK. 2006. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 8: 2390-2399.
66. Guirado E, Amat I, Gil O, Diaz J, Arcos V, Caceres N, Ausina V, Cardona PJ. 2006. Passive serum therapy with poly-clonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 8: 1252-1259.
67. Gupta S, Bhatia R, Datta KK. 1997. Serological diagnosis of childhood tuberculosis by estimation of mycobacterial antigen 60-specific immunoglobulins in the serum. Tuber LungDis 78: 21-27.
68. Hamasur B, Haile M, Pawlowski A, Schroder U, Williams A, Hatch G, Hall G, Marsh P, Kallenius G, Svenson SB. 2003. Mycobacterium tuberculosis arabinomannan-pro-tein conjugates protect against tuberculosis. Vaccine 21: 4081-4093.
69. Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. 2004. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 138: 30-38.
70. Hernandez J, Velazquez C, Valenzuela O, Robles-Zepeda R, Ruiz-Bustos E, Navarro M, Garibay-Escobar A. 2010. Low number of peripheral blood B lymphocytes in patients with pulmonary tuberculosis. Immunol Invest 39: 197-205.
71. Hetland G, Wiker HG, Hogasen K, Hamasur B, Svenson SB, Harboe M. 1998. Involvement ofantilipoarabinomannan antibodies in classical complement activation in tuberculosis. Clin Diagn Lab Immunol 5: 211-218.
72. Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA, Basaraba RJ, Lenaerts AJ. 2011. Location of intra-and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS ONE 6: e17550.
73. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, et al. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2: 893-898.
74. Igietseme JU, Eko FO, He Q, Black CM. 2004. Antibody regulation of T-cell immunity: Implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 3: 23-34.
75. Ireton GC, Greenwald R, Liang H, Esfandiari J, Lyashchenko KP, Reed SG. 2010. Identification of Mycobacterium tuberculosis antigens ofhigh serodiagnostic value. Clin Vaccine Immunol 17: 1539-1547.
76. Isaacs D. 2013. Infectious risks associated with biologics. Adv Exp Med Biol 764: 151-158.
77. Johnson CM, Cooper AM, Frank AA, Bonorino CB, Wysoki LJ, Orme IM. 1997. Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Tuber Lung Dis 78: 257-261.
78. Kalergis AM, Ravetch JV. 2002. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J Exp Med 195: 1653-1659.
79. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, Bishai WR. 2004. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 200: 647-657.
80. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345: 1098-1104.
81. Keyser A, Troudt JM, Taylor JL, Izzo AA. 2011. BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity. Vaccine 29: 9308-9315.
82. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, Visser A, Wang W, Hsu FF, Wiehart U, et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med 2: 258-274.
83. Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, Matsuzaki G, Arakawa T. 2008. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonarydissem-ination of Mycobacterium bovis bacillus Calmette-Gue-rin (BCG) in infected mice. Vaccine 26: 924-932.
84. Kondratieva TK, Rubakova EI, Linge IA, Evstifeev VV, Majorov KB, Apt AS. 2010. B cells delay neutrophil migration toward the site ofstimulus: Tardiness critical for effective bacillus Calmette-Guerin vaccination against tuberculosis infection in mice. J Immunol 184: 1227-1234.
85. Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, Flynn JL, Porcelli SA, Jacobs WR Jr., Chan J. 2013a. B cells regulate neutrophilia during Mycobacteri-um tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog 9: e1003472.
86. Kozakiewicz L, Phuah J, Flynn J, Chan J. 2013b. The role ofB cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol 783: 225-250.
87. Kunnath-Velayudhan S, Salamon H, Wang HY, Davidow AL, Molina DM, Huynh VT, Cirillo DM, Michel G, Talbot EA, Perkins MD, et al. 2010. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci 107: 14703-14708.
88. Kunnath-Velayudhan S, Davidow AL, Wang HY, Molina DM, Huynh VT, Salamon H, Pine R, Michel G, Perkins MD, Xiaowu L, et al. 2012. Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. J Infect Dis 206: 697-705.
89. Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldonk MJ, Verbon A, van Deventer SJ, van der Poll T. 2001. Depletion ofalveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166: 4604-4611.
90. Leemans JC, Thepen T, Weijer S, Florquin S, van Rooijen N, van de Winkel JG, van der Poll T. 2005. Macrophages play a dual role during pulmonary tuberculosis in mice. J Infect Dis 191: 65-74.
91. Lewinsohn DA, Gold MC, Lewinsohn DM. 2011. Views of immunology: Effector T cells. Immunol Rev 240: 25-39.
92. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, Chiosea I, Capuano SV, Fuhrman C, Klein E, et al. 2009. Quantitative comparison ofactive and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77: 4631-4642.
93. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, Su LF, Cubas R, Davis MM, Sette A, et al. 2013. Human circulating PD+CXCR3~CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity39: 758-769.
94. Lopez Y, Yero D, Falero-Diaz G, Olivares N, Sarmiento ME, Sifontes S, Solis RL, Barrios JA, Aguilar D, Hernandez-Pando R, et al. 2009. Induction of a protective response with an IgA monoclonal antibodyagainst Mycobacterium tuberculosis 16 kDa protein in a model of progressive pulmonary infection. Int JMed Microbiol 299: 447-452.
95. Lux A, Aschermann S, Biburger M, Nimmerjahn F. 2010. The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis 69 (Suppl 1): i92-i96.
96. Lyashchenko K, Colangeli R, Houde M, Al Jahdali H, Men-zies D, Gennaro ML. 1998. Heterogeneous antibody responses in tuberculosis. Infect Immun 66: 3936-3940.
97. Lyashchenko KP, Greenwald R, Esfandiari J, Greenwald D, Nacy CA, Gibson S, Didier PJ, Washington M, Szczerba P, Motzel S, et al. 2007. PrimaTB STAT-PAK assay, a novel, rapid lateral-flow test for tuberculosis in nonhuman primates. Clin Vaccine Immunol 14: 1158-1164.
98. Lyashchenko KP, Greenwald R, Esfandiari J, Chambers MA, Vicente J, Gortazar C, Santos N, Correia-Neves M, Bud-dle BM, Jackson R, et al. 2008. Animal-side serologic assay for rapid detection of Mycobacterium bovis infection in multiple species of free-ranging wildlife. Vet Microbiol 132: 283-292.
99. Lyashchenko KP, Greenwald R, Esfandiari J, Mikota S, Miller M, Moller T, Vogelnest L, Gairhe KP, Robbe-Austerman S, Gai J, et al. 2012. Field application of serodiagnostics to identify elephants with tuberculosis prior to case confirmation byculture. Clin VaccineImmunol 19: 1269-1275.
100. Ma CS, Deenick EK, Batten M, Tangye SG. 2012. The origins, function, and regulation ofT follicular helpercells. J ExpMed 209: 1241-1253.
101. Maglione PJ, Chan J. 2009. How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 39: 676-686.
102. Maglione PJ, Xu J, Chan J. 2007. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonarychallenge with Mycobacterium tuberculosis. J Immunol 178: 7222-7234.
103. Maglione PJ, Xu J, Casadevall A, Chan J. 2008. Fc g receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 180: 3329-3338.
104. Malik ZA, Denning GM, Kusner DJ. 2000. Inhibition of Ca2+ signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J Exp Med 191: 287-302.
105. Manivannan S, Rao NV, Ramanathan VD. 2012. Role of complement activation and antibody in the interaction between Mycobacterium tuberculosis and human macro-phages. Indian J Exp Biol 50: 542-550.
106. McClelland EE, Nicola AM, Prados-Rosales R, Casadevall A. 2010. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 120: 1355-1361.
107. Moir S, Fauci AS. 2009. B cells in HIV infection and disease. Nat Rev Immunol 9: 235-245.
108. Mossalayi MD, Vouldoukis I, Mamani-Matsuda M, Kauss T, Guillon J, Maugein J, Moynet D, Rambert J, Desplat V, Mazier D, et al. 2009. CD23 mediates antimycobacterial activityofhuman macrophages. Infect Immun 77: 5537-5542.
109. Nimmerjahn F, Ravetch JV. 2008. Fcg receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
110. Niu H, Hu L, Li Q, Da Z, Wang B, Tang K, Xin Q, Yu H, Zhang Y, Wang Y, et al. 2011. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine 29: 9451-9458.
111. North RJ, LaCourse R, Ryan L, Gros P. 1999. Consequence of Nramp1 deletion to Mycobacterium tuberculosis infection in mice. Infect Immun 67: 5811-5814.
112. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr., Casa-devall A. 2003. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest 112: 1164-1175.
113. Nussbaum G, Yuan R, Casadevall A, Scharff MD. 1996. Im-munoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med 183: 1905-1909.
114. Olivares N, Leon A, Lopez Y, Puig A, Cadiz A, Falero G, Martinez M, Sarmiento ME, Farinas M, Infante JF, et al. 2006. The effect of the administration of human g globulins in a model of BCG infection in mice. Tuberculosis (Edinb) 86: 268-272.
115. Ottenhoff TH. 2012. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 20: 419-428.
116. OttenhoffTH, Kaufmann SH. 2012. Vaccines against tuberculosis: Where are we and where do we need to go? PLoS Pathog 8: e1002607.
117. Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Fattorini L, Del Giudice G, Cassone A. 2008. The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-g response. Vaccine 26: 4237-4243.
118. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, Menozzi FD. 2001. The heparin-binding haemagglutinin ofM. tuberculosis is required for extrapulmonarydissem-ination. Nature 412: 190-194.
119. Pillai S. 2013. Love the one you're with: The HIV, B cell and TFH cell triangle. Nat Med 19: 401-402.
120. Pohl MA, Rivera J, Nakouzi A, Chow SK, Casadevall A. 2013. Combinations of antibodies to anthrax toxin manifest emergent properties in neutralization assays. Infect Immun 81: 1880-1888.
121. Rafiq K, Bergtold A, Clynes R. 2002. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110: 71-79.
122. Roca FJ, Ramakrishnan L. 2013. TNF dually mediates resistance and susceptibility to mycobacteria via mitochon-drial reactive oxygen species. Cell 153: 521-534.
123. Rodriguez A, Tjarnlund A, Ivanji J, Singh M, Garcia I, Williams A, Marsh PD, Troye-Blomberg M, Fernandez C. 2005. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 23: 2565-2572.
124. Roy E, Stavropoulos E, Brennan J, Coade S, Grigorieva E, Walker B, Dagg B, Tascon RE, Lowrie DB, Colston MJ, et al. 2005. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 73: 6101-6109.
125. Rubbert-Roth A. 2012. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 51 (Suppl 5): v38-v47.
126. Ruderman EM. 2012. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 51 (Suppl 6): vi37-vi43.
127. Russo RT, Mariano M. 2010. B-1 cell protective role in murine primary Mycobacterium bovis bacillus Calmette-Guerin infection. Immunobiology 215: 1005-1014.
128. Sada E, Ferguson LE, Daniel TM. 1990. An ELISA for the serodiagnosis of tuberculosis using a 30,000-Da native u antigen of Mycobacterium tuberculosis. J Infect Dis 162: 928-931.
129. Saylor C, Dadachova E, Casadevall A. 2009. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27 (Suppl 6): G38-G46.
130. Schmitt N, Ueno H. 2013. Blood Tfh cells come with colors. Immunity 39: 629-630.
131. Schoels M, Aletaha D, Smolen JS, Wong JB. 2012. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: Systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71: 1303-1308.
132. Schwebach JR. 2002. "The carbohydrate surface of M. tuberculosis: Antigenicity and antibody immunity." Thesis. Sue Golding Graduate Division of Medical Sciences. Albert Einstein College of Medicine, Bronx, NY.
133. Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, Selman M, Becerril-Villanueva E, Baquera-Heredia J, Pavon L, et al. 2013. CXCR5+ T helper cells mediate protective immunity against tuberculosis. JClin Invest 123: 712-726.
134. Smith MB, Boyars MC, Veasey S, Woods GL. 2000. Generalized tuberculosis in the acquired immune deficiency syndrome. Arch Pathol Lab Med 124: 1267-1274.
135. Suga M, Tanaka F, Muranaka H, Nishikawa H, Ando M. 1996. Effect of antibacterial antibody on bactericidal activities of superoxide and lysosomal enzyme from alveolar macrophages in rabbits. Respirology 1: 127-132.
136. Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, et al. 2013. Differential gene expression of activating Fcg receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 20: O230-O238.
137. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028
138. Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E, Casadevall A, Bloom BR. 1998. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci 95: 15688-15693.
139. Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, Macedo GC, Oliveira SC. 2006. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol 13: 930-935.
140. Tjarnlund A, Rodriguez A, Cardona PJ, Guirado E, Ivanyi J, Singh M, Troye-Blomberg M, Fernandez C. 2006. Polymeric IgR knockout mice are more susceptible to myco-bacterial infections in the respiratory tract than wild-type mice. Int Immunol 18: 807-816.
141. Townsend MJ, Monroe JG, Chan AC. 2010. B-cell targeted therapies in human autoimmune diseases: An updated perspective. Immunol Rev 237: 264-283.
142. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, Tufariello J, Flynn J, Chan J. 2006. Characterization ofthe tuberculous granuloma in murine and human lungs: Cellular composition and relative tissue oxygen tension. Cell Microbiol 8: 218-232.
143. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann SH. 2004. Human tuberculous granulomas induce peripheral lym-phoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 204: 217-228.
144. Vinuesa CG. 2012. HIVand T follicular helper cells: A dangerous relationship. J Clin Invest 122: 3059-3062.
145. Vinuesa CG, Tangye SG, Moser B, Mackay CR. 2005. Follicular B helper T cells in antibody responses and autoim-munity. Nat Rev Immunol 5: 853-865.
146. Vordermeier HM, Venkataprasad N, Harris DP, Ivanyi J. 1996. Increase of tuberculous infection in the organs of B cell-deficient mice. Clin Exp Immunol 106: 312-316.
147. Vouldoukis I, Mazier D, Moynet D, Thiolat D, Malvy D, Mossalayi MD. 2011. IgE mediates killing of intracellu-lar Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS ONE 6: e18289.
148. Weiner LM, Surana R, Wang S. 2010. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
149. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J. 2004. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 111: 328-333.
150. Xue T, Stavropoulos E, Yang M, Ragno S, Vordermeier M, Chambers M, Hewinson G, Lowrie DB, Colston MJ, Tascon RE. 2004. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacte-rium tuberculosis infection. Infect Immun 72: 6324-6329.
151. Yano M, Gohil S, Coleman JR, Manix C, Pirofski LA. 2011. Antibodies to Streptococcus pneumoniae capsular poly-saccharide enhance pneumococcal quorum sensing. mBio 2: e0076-11.
152. Yao S, Huang D, Chen CY, Halliday L, Wang RC, Chen ZW. 2014. CD4+ T cells contain early extrapulmonary tuberculosis (TB) dissemination and rapid TB progression and sustain multieffector functions of CD8+ T and CD3-lymphocytes: Mechanisms of CD4+ T cell immunity. J Immunol 192: 2120-2132.
153. Yu X, Prados-Rosales R, Jenny-Avital ER, Sosa K, Casadevall A, Achkar JM. 2012. Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status. Clin Vaccine Immunol 19: 198-208.
154. Zhang M, Zheng X, Zhang J, Zhu Y, Zhu X, Liu H, Zeng M, Graner MW, Zhou B, Chen X. 2012. CD19+CD1d+CD5+ B cell frequencies are increased in patients with tuberculosis and suppress Th17 responses. Cell Immunol 274: 89-97.
155. Ziegenbalg A, Prados-Rosales R, Jenny-Avital ER, Kim RS, Casadevall A, Achkar JM. 2013. Immunogenicityofmy-cobacterial vesicles in humans: Identification of a new tuberculosis antibody biomarker. Tuberculosis (Edinb) 93: 448-455.